• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接受替泊替尼治疗的非小细胞肺癌患者的肾损伤

Kidney Injury in Patient with Non-small-cell Lung Cancer Receiving Tepotinib.

作者信息

Oda Naohiro, Onishi Akifumi, Mitani Reo, Tokura Takehiko, Takata Ichiro

机构信息

Department of Internal Medicine, Fukuyama City Hospital, Japan.

出版信息

Intern Med. 2025 Jul 1;64(13):2019-2023. doi: 10.2169/internalmedicine.4488-24. Epub 2024 Dec 5.

DOI:10.2169/internalmedicine.4488-24
PMID:39631863
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12287581/
Abstract

We herein report a 68-year-old man with advanced non-small-cell lung cancer treated with tepotinib who showed marked general edema, hypoalbuminemia, and an elevated serum creatinine level. Although tepotinib-induced kidney injury due to creatinine transporter inhibition has been reported, renal biopsy findings suggested tubulointerstitial injury due to decreased renal blood flow, likely secondary to refractory fluid retention. This case highlights the potential for true kidney injury during tepotinib therapy and underscores the importance of careful monitoring and management of adverse renal effects.

摘要

我们在此报告一名68岁患有晚期非小细胞肺癌的男性，接受了替泊替尼治疗，出现了明显的全身性水肿、低白蛋白血症和血清肌酐水平升高。虽然已有报道替泊替尼因抑制肌酐转运蛋白而导致肾损伤，但肾活检结果提示肾小管间质损伤是由于肾血流量减少所致，可能继发于难治性液体潴留。该病例凸显了替泊替尼治疗期间发生真正肾损伤的可能性，并强调了仔细监测和管理肾不良影响的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0322/12287581/6479cfac9be1/1349-7235-64-13-2019-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0322/12287581/2fbf000ce207/1349-7235-64-13-2019-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0322/12287581/acb4b5234d61/1349-7235-64-13-2019-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0322/12287581/de38efac31d8/1349-7235-64-13-2019-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0322/12287581/119ec78f18e6/1349-7235-64-13-2019-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0322/12287581/6479cfac9be1/1349-7235-64-13-2019-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0322/12287581/2fbf000ce207/1349-7235-64-13-2019-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0322/12287581/acb4b5234d61/1349-7235-64-13-2019-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0322/12287581/de38efac31d8/1349-7235-64-13-2019-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0322/12287581/119ec78f18e6/1349-7235-64-13-2019-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0322/12287581/6479cfac9be1/1349-7235-64-13-2019-g005.jpg

相似文献

1
Kidney Injury in Patient with Non-small-cell Lung Cancer Receiving Tepotinib.接受替泊替尼治疗的非小细胞肺癌患者的肾损伤
Intern Med. 2025 Jul 1;64(13):2019-2023. doi: 10.2169/internalmedicine.4488-24. Epub 2024 Dec 5.
2
Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations.特泊替尼治疗伴有外显子 14 跳跃突变的非小细胞肺癌。
N Engl J Med. 2020 Sep 3;383(10):931-943. doi: 10.1056/NEJMoa2004407. Epub 2020 May 29.
3
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring exon 14 mutation: a research report.携外显子 14 突变脑转移的非小细胞肺癌患者使用 tepotinib 后的长期生存和疗效：研究报告。
Cold Spring Harb Mol Case Stud. 2020 Dec 17;6(6). doi: 10.1101/mcs.a005785. Print 2020 Dec.
4
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.比较伴有 ALK 重排的晚期非小细胞肺癌一线治疗的疗效和安全性：临床试验的荟萃分析。
BMC Cancer. 2021 Nov 26;21(1):1278. doi: 10.1186/s12885-021-08977-0.
5
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.基于替泊替尼和奥美拉唑联合用药的KRAS突变型非小细胞肺癌（NSCLC）治疗
Cell Commun Signal. 2024 Jun 12;22(1):324. doi: 10.1186/s12964-024-01667-x.
6
Capmatinib successfully overcomes tepotinib-induced intolerable peripheral edema.卡马替尼成功克服了替泊替尼引起的无法耐受的外周水肿。
Thorac Cancer. 2021 Dec;12(24):3426-3428. doi: 10.1111/1759-7714.14205. Epub 2021 Oct 25.
7
Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.用于鉴定MET外显子14跳跃型非小细胞肺癌的液体活检和组织活检：来自替泊替尼II期VISION研究的分析
Clin Cancer Res. 2025 Jul 1;31(13):2675-2684. doi: 10.1158/1078-0432.CCR-24-4097.
8
Gefitinib for advanced non-small cell lung cancer.吉非替尼用于治疗晚期非小细胞肺癌。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):CD006847. doi: 10.1002/14651858.CD006847.pub2.
9
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.在日本实体瘤患者中进行的 MET 抑制剂 tepotinib 的 I 期临床试验。
Jpn J Clin Oncol. 2020 Aug 4;50(8):859-866. doi: 10.1093/jjco/hyaa042.
10
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.

本文引用的文献

1
Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.简报：抑制 MATE-1 的酪氨酸激酶抑制剂可导致“虚假”的肾功能下降。
J Thorac Oncol. 2024 Jan;19(1):153-159. doi: 10.1016/j.jtho.2023.09.1444. Epub 2023 Sep 23.
2
Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker.与靶向抗癌药物相关的假性急性肾损伤——真相存在于滤过标志物之中。
Clin Kidney J. 2023 Jan 16;16(4):603-610. doi: 10.1093/ckj/sfad011. eCollection 2023 Apr.
3
Pseudo-acute kidney injury secondary to tepotinib.
特泊替尼继发的假性急性肾损伤
Clin Kidney J. 2022 Aug 1;16(4):760-761. doi: 10.1093/ckj/sfac180. eCollection 2023 Apr.
4
Impact of trimethoprim on serum creatinine, sodium, and potassium concentrations in patients taking trimethoprim-sulfamethoxazole without changes in glomerular filtration rate.在肾小球滤过率没有变化的情况下，服用甲氧苄啶-磺胺甲恶唑的患者中，甲氧苄啶对血清肌酐、钠和钾浓度的影响。
J Clin Pharm Ther. 2022 Sep;47(9):1409-1417. doi: 10.1111/jcpt.13679. Epub 2022 May 11.
5
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.替泊替尼治疗 MET 外显子 14 跳跃型非小细胞肺癌患者的疗效和安全性：VISION 研究中与临床实践相关的患者亚组的结果。
Clin Cancer Res. 2022 Mar 15;28(6):1117-1126. doi: 10.1158/1078-0432.CCR-21-2733.
6
Capmatinib-Induced Pseudo-Acute Kidney Injury: A Case Report.卡马替尼诱导的假性急性肾损伤：一例报告。
Am J Kidney Dis. 2022 Jan;79(1):120-124. doi: 10.1053/j.ajkd.2021.04.009. Epub 2021 Jun 9.
7
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.MET 外显子 14 跳跃型非小细胞肺癌患者接受 tepotinib 治疗：来自 II 期 VISION 研究的日本亚组分析。
Jpn J Clin Oncol. 2021 Aug 1;51(8):1261-1268. doi: 10.1093/jjco/hyab072.
8
Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations.特泊替尼治疗伴有外显子 14 跳跃突变的非小细胞肺癌。
N Engl J Med. 2020 Sep 3;383(10):931-943. doi: 10.1056/NEJMoa2004407. Epub 2020 May 29.
9
Clinical practice guideline for drug-induced kidney injury in Japan 2016: digest version.《2016年日本药物性肾损伤临床实践指南：摘要版》
Clin Exp Nephrol. 2016 Dec;20(6):827-831. doi: 10.1007/s10157-016-1334-0.
10
HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.肝细胞生长因子/间质-上皮转化因子导向疗法在胃食管癌中的应用：临床与生物标志物发展综述
Oncotarget. 2014 May 30;5(10):2866-80. doi: 10.18632/oncotarget.2003.